D&D Pharmatech Inc. Logo

D&D Pharmatech Inc.

Clinical-stage biopharma developing GLP-1 therapies for metabolic and neurodegenerative diseases.

347850 | KO

Overview

Corporate Details

ISIN(s):
KR7347850000
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 금토로80번길 27 (금토동, 텔레칩스) 4층, 성남시

Description

D&D Pharmatech is a clinical-stage biopharmaceutical company specializing in the development of therapies based on GLP-1 (Glucagon-like peptide-1) and related peptides. The company's pipeline primarily targets metabolic diseases, including obesity and MASH (Metabolic dysfunction-associated steatohepatitis), as well as neurodegenerative disorders. A core competency is its proprietary oral peptide delivery technology. Key candidates in its portfolio include DD01, an injectable dual GLP-1/glucagon receptor agonist for MASH that has received FDA Fast Track Designation, and an oral GLP-1 therapy for obesity. The company operates a global model, funding drug development through specialized subsidiaries, with research functions in Korea and clinical development managed by its US-based team.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-13 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-06-11 00:00
주요사항보고서(자본으로인정되는채무증권발행결정)
Korean 31.4 KB
2025-06-11 00:00
주요사항보고서(전환사채권발행결정)
Korean 101.9 KB
2025-06-11 00:00
주요사항보고서(타법인주식및출자증권양수결정)
Korean 90.5 KB
2025-06-10 00:00
주식등의대량보유상황보고서(약식)
Korean 162.2 KB
2025-05-15 00:00
주식등의대량보유상황보고서(일반)
Korean 85.7 KB
2025-05-14 00:00
기업설명회(IR)개최
Korean 6.7 KB
2025-05-13 00:00
분기보고서 (2025.03)
Korean 1.2 MB
2025-04-28 00:00
기업설명회(IR)개최
Korean 6.8 KB
2025-03-28 00:00
정기주주총회결과
Korean 27.5 KB
2025-03-28 00:00
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 13.0 KB
2025-03-20 00:00
감사보고서제출
Korean 26.5 KB
2025-03-20 00:00
사업보고서 (2024.12)
Korean 2.0 MB
2025-03-19 00:00
기업설명회(IR)개최
Korean 6.8 KB
2025-03-13 00:00
기업설명회(IR)개최
Korean 7.0 KB

Automate Your Workflow. Get a real-time feed of all D&D Pharmatech Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for D&D Pharmatech Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for D&D Pharmatech Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.